Aktis Oncology, Inc. (AKTS) vs Latigo Biotherapeutics Inc. (LTGO)

A side-by-side comparison of Aktis Oncology, Inc. and Latigo Biotherapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AKTS

Aktis Oncology, Inc.

$980M

$18.35HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT

LTGO

Latigo Biotherapeutics Inc.

$1.01B

$16.75HealthcareDelayed quote: Oct 6, 2026, 12:10 PM EDT

Total return — AKTS vs LTGO

growth of $100 · dividends reinvested · last 1y

AKTS -21.0% (-21.0%/yr)LTGO -7.6% (-7.6%/yr)LTGO compounded faster over this window

AKTS LTGO

Metrics side by side

LTGO is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full AKTS analysis Full LTGO analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.